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Abstract
Pluripotent stem cells can be successfully isolated from a variety of tissues from adult 
organisms. This fact opens the exciting possibility of cell-based therapies for a large num-
ber of clinical treatments. However, the development of optimized protocols to obtain, 
grow, and cryopreserve cells, as well as that of effective clinical treatment procedures, is 
no easy task. The therapeutic potential of cells expanded in vitro depends on a multitude 
of factors including isolation procedures, donor and tissue types, expansion and preser-
vation methods, etc. Researchers are investing great efforts to determine which of these 
many variables significantly impact downstream performance of in vitro expanded stem 
cells by studying associated changes in molecular profiles and their effect on the host 
immune system. This chapter reviews the current status of stem cell production and its 
derivatives, which are paving the way to different treatments in the clinic. Due to the 
research interests of our labs, particular emphasis is placed on the potential benefits of 
stem cell-based therapeutics for the treatment of spinal cord injuries and the neuroim-
mune disease myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) not only 
derived from differentiation and cell engraftment mechanisms but also due to the anti-
inflammatory and immunoregulatory capacities of these cells.
Keywords: mesenchymal stem cell (MSC), induced pluripotent stem cell (iPSC), spinal 
cord injury (SCI), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 
extracellular vesicle (EV)
1. Introduction
Stem cells present particular characteristics that make them different from other cell types. 
Firstly, they are unspecialized self-renewing tissue resident cells, and secondly they can be 
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induced to differentiate into a milieu of specialized cell types, thus holding promise for regen-
erative medicine. When these cells are isolated from adult fully differentiated tissues, they 
receive the attribute of adult stem cells, even though they are also present in infants and fetus. 
Therefore, it would be more appropriate to refer to them as tissue stem cells or mesenchymal 
stem cells to differentiate them from resident progenitors with limited differentiation capac-
ity. MSCs can be isolated from a large number of tissues, such as bone marrow, adipose tissue, 
dental pulp, hair follicles, amniotic fluid, Wharton’s jelly in the umbilical cord, and even from 
nervous or cardiac tissue. MSCs are multipotent and can be differentiated into chondrocytes, 
adipocytes, and osteoblasts under proper conditions [1, 2]. MSCs can be cloned and expanded 
in vitro more than a million fold without losing their differentiation potential [3] constituting, 
theoretically, a rich resource for tissue repair. However, their sensitivity to environmental 
cues and genetic factors together with a lack of standardized good manufacturing procedures 
(GMPs) using defined components has hampered their true therapeutic potential. Since the 
finding by Bartholomew et al. that MSCs inhibit mixed lymphocyte reactions and prevent the 
rejection of allogeneic skin grafts [4], a large number of reports have evidenced that MSCs are 
immunosuppressive and immunoregulatory, properties that can be harnessed therapeutically. 
However, challenges to fully understand and control MSC regenerative potential remain.
In addition to MSC, the reprograming of terminally differentiated cells or induction of de-differ-
entiation by the introduction of particular sets of transcription factors [5–7] opened an additional 
avenue of opportunities in the field of regenerative medicine. iPScs or induced pluripotent stem 
cells facilitate the production of patient-specific cells overcoming immune rejection and also 
ethical concerns. Although they have shown their value in the generation of in vitro models 
of human disease [8, 9], the low efficiency of reprogramming events and the safety concerns 
associated with the process of reprogramming has prevented their use in the clinic [6, 10].
Based on the research interests of our labs, this chapter, while reviewing the advances to gen-
erate clinical-grade stem cells or their by-products, highlights the potential benefits of stem 
cell-based therapeutics for the treatment of spinal cord injuries (SCI) and the neuroimmune 
disease myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
2. Stem cell therapy for spinal cord repair
2.1. Spinal cord injury pathological events and timing sequence
Spinal cord injury (SCI) is often mentioned among the first conditions for which stem cells may 
provide a new therapy. While recent decades have brought significant improvements in res-
cuing neuronal activity after SCI at preclinical phases testing several individual approaches, 
translation to the clinic still remains inefficiently explored. Management for SCI efficient 
treatment is a difficult task by the intrinsic nature of the pathological cascade of events that 
makes the SCI a dynamic and progressive disorder. The sentence “Time is spine” defines the 
crucial importance of timing to rapidly diagnose patients and implement neuroprotective 
interventions during the acute injury phase (≤2 h) in order to diminish the devastating effects 
of the secondary phase of the injury (≥2–48 h) which are known to be key determinants of the 
final extent of neurological deficits. The secondary injury leads to necrosis and/or apoptosis 
of neurons and glial cells, such as oligodendrocytes, which can lead to demyelination and 
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the loss of neural circuits. Later, in a subacute phase (2–4 days after injury), further ischemia 
occurs owing to ongoing edema, vessel thrombosis, and vasospasm. Persistent inflammatory 
cell infiltration causes further cell death and formation of very toxic cystic microcavities over 
time. Astrocytes, fibroblast, and pericytes proliferate and deposit extracellular matrix mol-
ecules into the perilesional area in the already intermediate and chronic phases, few weeks 
after SCI, when axons continue degenerating (Figure 1a) [11].
Spontaneous regeneration during and after having reached the chronic stage occurs due to 
the neuroplasticity capacity of the central nervous system (CNS); however, very limited gain 
of function is obtained decreasing advancing age, attributed to both extrinsic and intrinsic fac-
tors that modulate further onset, severity, and progression of the injury [12]. The cumulative 
myelin-associated protein anchorage to myelin sheet debris, in and around the epicenter of the 
injury, has a strong inhibitory nature. Nogo-A (reticulon-4 isoform A) and myelin-associated 
glycoprotein (MAG), among other myelin-associated proteins, bind to NOGO receptors to acti-
vate the GTPase Rho A, which activates Rho-associated protein kinase (ROCK), a regulator of 
further downstream effectors, leading to apoptosis and growth-cone collapse of regenerating 
axons involving neurite retraction [13–17]. Additional external barriers are potently adding to 
the inhibition of regeneration like the hypertrophic astrocytes and the reactive chemical scar 
with a number of axonal growth inhibitory chondroitin sulfate proteoglycans (CSPGs) [18].
The chronic SCI repair demands an intensive effort to overcome the impediments and enhance 
the intrinsic axon regeneration involving an efficient anatomical reorganization [19, 20]. 
Fortunately, although long distances for axonal reconnection or spared degenerated tracts are 
normally required, involving a long-term process (a rate of 1 mm/month for axon growth is 
estimated), it has been shown that as little as 10% of particular tracts can subserve substantial 
function [19, 20]. This in fact allows hypothesizing for a real recovery, mediated by bridging 
and partially reconnecting the spared axons allowing subsequent plasticity. Additionally, 
both, humans and rats, can regain a degree of function after incomplete injury, thought to be 
mostly due to local structural rearrangements, such as collateral sprouting from remaining 
axons in the gray matter, rather than by long-distance regeneration of axons in the white 
matter (Figure 1b) [21].
2.2. Stem cell therapy for SCI repair
Cell transplantation methods constitute a very promising strategy for SCI repair. Numerous 
studies with a diversity of cell types have clearly showed benefits to different extents, for 
Figure 1. Summary of physiopathological events after SCI (a) and stem cell transplantation (b).
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instance, therapeutic effects in sensorimotor function recovery in preclinical models [22, 23] 
and in several ongoing clinical trials [24–26].
Among these cell types used, mesenchymal stem cells (MSCs) from the adipose tissue, bone 
marrow [27], umbilical cord, [28] or dental pulp [29], in addition to olfactory ensheathing glial 
(OEG) cells [30], Schwann cells [31], or neural precursor cells [32], have been used.
Preclinical studies have shown that MSCs have potent anti-inflammatory, anti-apoptotic, 
immunomodulatory, and angiogenic effects post-SCI [33]. MSC transplantation, overall, 
results in substantially improved locomotor recovery among animal models of SCI [34]. There 
have also been several clinical trials using autologous bone marrow-derived MSCs. These 
early studies confirm the safety of different administration protocols using MSCs post-SCI. It 
seems that sufficient quantities of transplanted allogeneic MSCs combined with immunosup-
pression prolong the survival of engrafted cells and improve functional and morphological 
outcomes after SCI [35].
Transplantation of neural stem/progenitor cells (NSPCs) has shown promising results in the 
repair and regeneration of lost neural tissues and the associated restoration of neurological 
deficits [36] with particular benefits among other cell types. The engrafted transplanted NSPCs 
generate a favorable non-inhibitory environment for functional recovery creating additional 
paracrine activity modulating the post-SCI inflammatory response, feeding the injured area 
with growth factors, and rendering additional neurotrophic support by releasing, among oth-
ers, GDNF. NSPCs include multipotent stem cells present in the ependymal region lining the 
central canal of the spinal cord (epSPC) [37]. epSPC represents an ideal candidate for stem 
cell therapy based on noted functional improvements after transplantation and the absence of 
malignant transformation, offering a safe and relevant cell type for clinical applications. The 
rationale for the therapeutic application of epSPC for SCI includes the replacement of dam-
aged neurons and glial cells, secretion of trophic factors, regulation of gliosis and scar forma-
tion, prevention of cyst formation, and enhancement of axon elongation. After SCI, epSPCs 
proliferate and migrate to the injured area and produce new oligodendrocyte precursor cells 
(OPCs) [37]. Acute [38] and chronic [39] transplantation of undifferentiated epSPCs from 
SCI donors or in vitro differentiated OPCs into a rat model of severe spinal cord contusion 
produced significant locomotion recovery 1 week after injury. Transplantation of epSPCs pro-
vides trophic support and positively modulates the local immune response. It reduces puri-
nergic receptor expression associated with neurodegenerative and neuropathic pain, thereby 
inducing signals promoting neuronal protection and survival with axonal outgrowth [40]. 
Interestingly, an immortalized human fetal epSPC line (HuCNS-SC) has been the main focus 
of cell therapies developed by the company Neuralstem, Inc. (USA), and therapies based on 
this product have been applied to human subjects in a phase II clinical trial. Phase I/II trial has 
declared no adverse effects of treatment, with modest functional improvements [41].
Stem cell therapy can contribute to SCI repair not only by restoring the damaged tissue 
through differentiation and engraftment but also by potentiating endogenous tissue regener-
ative potential. Both processes are influenced by the action of the immune system controlling 
local inflammation, and thus stem cell paracrine factor role in this context should be carefully 
evaluated.
Cell Culture114
3. Stem cell therapy for other neuroimmune-related health problems: 
potential benefits for the treatment of myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS)
Mesenchymal stromal cells (MSCs) have been used in clinical trials (CTs) for a broad range 
of immune-related health problems such as acute and chronic inflammatory disorders, 
autoimmune diseases, and transplant rejection by their potent immunosuppressive and anti-
inflammatory properties [42–45]. As reviewed by Wang et al., as of April 2016, over 500 MSC-
related clinical trials were registered on the NIH clinical trial database (https://clinicaltrials.
gov/). Although the immunomodulatory properties of MSCs have more recently been identi-
fied, almost half of the registered CTs (230 or 42% of them) have or are being conducted for 
immune- or inflammation-mediated diseases (see Figure 2) [45].
Multiple sclerosis (MS) and its animal model (experimental autoimmune encephalomyelitis 
or EAE) associate with CNS inflammation, gliosis, demyelination, and axonal loss. MSCs’ 
pleiotropic properties, including immunomodulation, immunosuppression, neurotrophy, 
and repair-promotion, make them attractive candidates for the treatment of neurodegenera-
tive diseases, including MS [42–46]. The remyelination benefits reported in MS are largely 
attributed to paracrine signals and secreted soluble molecules such as tumor growth fac-
tor (TGF-β1), interferon (INF)-γ, indoleamine 2,3-dioxygenase (IDO), and prostaglandin E2 
(PGE2) [46–48]. On another side, neural precursors obtained from induced pluripotent stem 
cells (iPSCs) promote the viability of endogenous OPCs facilitating remyelination through 
the secretion of leukemia inhibitory factor (LIF) in EAE [46, 49–51]. LIF, a member of the IL-6 
cytokine family implicated in the pathophysiology of MS, has shown to offer neuroprotection 
and axonal regeneration as well as prevention of demyelination [49–51].
Figure 2. Summary of the number of clinical trials using MSC therapy in immune- or inflammation-mediated diseases, 
as registered on the website https://clinicaltrials.gov (accessed April 2016). MS, multiple sclerosis; T1DM, type 1 diabetes 
mellitus; GVHD, graft-versus-host disease; OA, osteoarthritis; IBD, inflammatory bowel disease (a). MSC-derived 
paracrine factors mediating immunomodulatory functions, particularly toward T lymphocytes, in preclinical animal 
studies of various immune- and inflammation-mediated diseases (b). Source: Wang et al. [45].
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Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multiorgan sys-
tem disease, often devastating, for which no single diagnostic test yet exists. The diagnosis of 
ME/CFS is based on exclusion, meaning other medical conditions, including psychiatric dis-
orders, must be first ruled out. The disease is characterized by profound fatigue and disability 
lasting for at least 6 months, episodes of cognitive dysfunction, sleep disturbance, autonomic 
abnormalities, chronic or intermittent pain syndromes, microbiome abnormalities [52], cerebral 
cytokine dysregulation [53, 54], natural killer cell dysfunction [55], and other symptoms that 
are made worse by exertion of any kind [56, 57]. The Institute of Medicine (IOM) recently pub-
lished an update of the diagnostic criteria recommended for CFS [56, 57]. The estimated world-
wide prevalence of ME/CFS is 0.4–1%. The disease predominantly affects young adults, with 
a peak age of onset of between 20 and 40 years, and women, with a female-to-male ratio of 6:1 
[58]. Although the etiological agent of ME/CFS remains unknown, the many hypotheses raised 
based on patient testimonies and clinical observations seem to lead to pathological immune 
system malfunctioning as one major factor. Autoimmune features on one side [59] and latent 
infection of unknown microorganisms, with a chronically activated immune system leading 
to inflammatory type situations, on another [60] have led our group to propose that stem cell-
based therapeutics, as evidenced for MS, might be of benefit to these patients as well. The World 
Health Organization (WHO) has classified ME/CFS as a neurological disorder (International 
Classification of Diseases, Tenth Revision, Clinical Modification or ICD-10-CM R53.82; G93.3 
if post-viral) based on the cognitive and other neurologic associated symptoms these patients 
suffer from. The neurological symptoms, however, could be explained by microglial activation 
and the lower-than-normal production of cortisol and adrenocorticotropic hormone (ACTH) 
these patients show, causing serotonin and corticotropin (CRH) deregulation [61]. A decrease 
in cortisol production by adrenal glands in turn can influence immune system activity [62]. 
MSC therapeutics could, at least partially, restore normal immune and, perhaps, neural func-
tioning. Preclinical safety studies, however, should precede CT in ME/CFS.
4. Current protocols for stem cell-based therapeutics
4.1. Mesenchymal stem cells (MSCs)
MSCs do not express major histocompatibility complex class I or II, permitting adoptive 
transfer between hosts without triggering acute rejection. In 2006, the International Society 
for Cellular Therapy (ISCT) established minimal criteria to define human MSCs as follows: 
MSC must be plastic-adherent when maintained in standard culture conditions; MSC must 
express CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14 or CD11b, CD79α 
or CD19, and HLA-DR surface molecules; and MSC must differentiate to osteoblasts, adi-
pocytes, and chondroblasts in vitro [63, 64]. The latter position paper adds to the original 
characterization criteria viability and proliferation features [64]. Cells that fulfill these criteria 
can be isolated from different sources (such as fat, bone marrow, umbilical cord blood, dental 
pulp, etc.), but tissue source, donor’s age, extent, and conditions of in vitro expansion, among 
others, are known to influence the regenerative potential based on engraftment, paracrine 
effects, and differentiation capacity of these cells [65]. Freeze-thawing effects on the whole 
genome expression profile of MSC have been observed, although they did not exceed inter-
donor differences [66]. This high inherent heterogeneity of MSCs remains a challenge for data 
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harmonization, particularly across lab comparisons. Despite this limitation, consensus good 
manufacturing procedures (cGMP) for large-scale clinical-grade MSC have been developed 
[67–69], based on original low-scale lab preparation methods consisting of tissue trimming, 
enzyme-based (collagenase) dissociation, cell filtration, and cell-type selection through adher-
ence to plastic and extended survival in vitro [70, 71].
Although the numbers of CT with MSCs are already considerable and increasing, only 13 
human MSC-based products count with marketing authorization. As shown in Table 1, nine 
are developed for allogeneic therapies and only four for autologous. The main source for 
MSC manufacturing is the bone marrow, followed by adipose tissue, although others such as 
umbilical cord, cord blood, placental tissue, and Wharton’s jelly are being explored. However, 
as ASCs (adipose stromal stem cells) possess similar therapeutic potential other than bone 
marrow MSCs as described by the ISCT and the International Federation of Adipose 
Therapeutics and Science (IFATS), and since they are obtained by minimally invasive proce-
dures from a generally undesired tissue, the fat, they may shortly become the main choice of 
adult stem cells for clinical applications. In fact, as reported by Nordberg and Loboa, clinical 
trials using ASC raised from 18 to 152 in less than 5 years (2010 to the first quarter of 2015) [72]. 
Standard procedures based on single-use bioreactors yield superior quantities and quality of 
cells when compared to traditional planar multilayer cultivation systems, such as CELLstack, 
HYPERStack, and CellFactories (Corning, Nalge) [67].
Efficient manufacture of MSC-based products also takes costs into account. Either allogeneic 
or autologous therapies involve cGMP upstream processing (USP) through master and work-
ing cell banks (MCB and WCB, respectively) and downstream processing (DSP) events, a 
summary of which are shown in Figure 3.
These manufacturing processes are tightly regulated by the Advanced Therapeutic Medicinal 
Product (ATMP) path [73], the European Medicines Agency (EMA) in Europe, the Center for 
Biologics Evaluation and Research/Food and Drug Administration (FDA) in the USA, and 
the Central Drugs Standard Control Organization in Asia (readers are directed to selected 
reviews for further legal regulatory details) [67, 73, 74].
A potential formulation to standardize cell source has been proposed by Yi et al. who using 
GMPs could expand clonal MSCs from a single colony-forming unit (CFU)-derived colonies 
derived from a small amount of bone marrow to treat a number of patients [75].
Typically, the conventional media used for clinical production of MSCs are the common, 
defined Dulbecco’s Modified Eagle Medium (DMEM) and Minimum Essential Medium 
(MEM) basal media supplemented with 10–20% fetal bovine serum (FBS), due to limitations 
of human alternatives and to cost reasons, although FBS is not cGMP compliant. FBS is prone 
to batch-to-batch variation and to contamination with prions, viral and zoonotic agents [76]. 
Thus, most clinical trials (phases I to III) used ASCs or other MSCs produced in the presence 
of FBS, some of them reporting immunogenic effects in patients, elicited by components of 
FBS (antibodies against components of FBS, Arthus, and anaphylactic reactions) [77–79]. In 
addition, the immune responses elicited by FBS could turn into rejection of the transplanted 
cells in cell-based therapies restricting their therapeutic efficacy. FBS-free alternatives can 
be basically grouped into serum-free (SF) medium containing animal-derived or human 
serum albumin and growth factors (GFs). Among human alternatives, the use of autologous 
products obviates the need for infectious or other pathological agent testing but limits the 
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production to few doses. The allogeneic alternative permits larger cell production by pooling 
samples from different donors but requires pathological agent screenings. Human deriva-
tives show improved proliferation when compared to FBS-supplemented media reducing 
the time for cell expansion and lowering threats of senescence and transformation; however, 
human serum seems to limit osteogenic differentiation [63, 64, 80], and human platelet-poor 
plasma limits chondrogenesis [81, 82], while human platelet-rich plasma or platelet lysate 
preserves trilineage differentiation [83–85]. In addition, human platelet lysate, obtained by 
temperature-shock protocols (freezing platelets from −30 to −80°C during 24 h followed by a 
thawing a centrifugation step), can be prepared from banked blood with 4 or 5 days passed 
expiration date [86], making platelet lysate a preferable choice. To avoid MSC senescence, 
forced expression of telomerase reverse transcriptase (TERT) has been tried [86, 87]; however, 
nongenetic manipulations will be more suitable for clinical translation. On another side, the 
serine/threonine kinase AKT activation by plasma rich in growth factors leads to enhanced 
Medicinal product Company hMSC type Indication Marketing authorization
Allostem AlloSource Allogeneic ASC Bone regeneration US medical device
Cartistem Medipost Allogeneic 
UCB-MSC
Osteoarthritis Korea
Grafix Osiris Therapeutics Allogeneic 
BM-MSC
Soft tissue defects US medical device
Prochymal Mesoblast Allogeneic 
BM-MSC
Graft-versus-host 
disease
Canada and New Zealand
OsteoCel NuVasive Allogeneic 
BM-MSC
Spinal bone 
regeneration
US medical device
OvationOS Osiris Therapeutics Allogeneic 
BM-MSC
Bone regeneration US medical device
TEMCELL HS JCR Pharmaceuticals Allogeneic 
BM-MSC
Graft-versus-host 
disease
Japan
Trinity Evolution Orthofix Allogeneic 
BM-MSC
Bone regeneration US medical device
Trinity Elite Orthofix Allogeneic 
BM-MSC
Bone regeneration US medical device
Hearticellgram-AMI Pharmicell Autologous 
BM-MSC
Acute myocardial 
infarction
Korea
Cupistem Anterogen Autologous ASC Crohn’s fistula Korea
QueenCell Anterogen Autologous ASC Regeneration of 
subcutaneous adipose 
tissue
Korea
Ossron RMS Autologous 
BM-MSC
Bone regeneration Korea
Source: Adapted from Jossen et al. [67]. ASC human adipose tissue-derived stromal/stem cells, BM-MSC human bone 
marrow-derived mesenchymal stem cells, and UCB-MSC umbilical cord-derived mesenchymal stem cells.
Table 1. MSC-based products with marketing authorization for allogeneic and autologous therapies
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survival and regenerative potential of MSCs and also confers resistance to hostile environ-
ments associated with inflammation which induces cell death by oxidative stress [88–90], 
evidencing the presence of GFs as a conditioning advantage for stem cell production.
Chemically defined, xeno-free medium does not involve donor or batch-to-batch variation; 
neither requires pathogenic agent screenings and presents minimal immunogenicity [91]. 
Drawbacks are the high cost of commercial versions and the fact that cells grown under 
these conditions lose their ability to adhere to plastic, requiring additional coating agent 
steps [92, 93]. Cells grown in xeno-free protocols also show improved proliferation potential 
when compared with FBS-based growing media with the previously mentioned consequent 
advantages [76, 92–94]. In addition to the choice of source of proteins and growth factors, 
basal media, seeding density, oxygen tension, confluency, and dissociation protocols may 
also influence outcomes. Further studies that carefully control growing conditions and at 
the time explore aspects such as senescence, genetic stability, immunogenicity and cytokine 
production, and transcriptome and proteome are needed.
In vivo ASCs reside under low oxygen tension (physioxia); Chen et al. have recently shown 
that the simulation of physioxic conditions (2% O
2
) instead of the typical atmospheric oxygen 
concentration used in cell culture (20–21%) leads to increased proliferation, migration, and 
angiogenesis plus decreased senescence and apoptosis suggesting that the maintenance of 
native bioactivities may translate into production of superior cell products [95].
It is clear that tissue source and optimal growing conditions for MSC manufacturing will 
depend on the needs of downstream applications. In this sense it is important to mention that 
Okolicsanyi et al. have shown that MSCs isolated from the bone marrow of normal donors 
Figure 3. Main operations required to manufacture clinical-grade human MSCs for allogeneic (A) or autologous (B) 
therapies. USP operations typically include manufacturing of the MCB and WCB, seed cell production, and expansion 
at a large scale. DSP steps include cell harvest, cell detachment and separation, washing, concentration procedures, and 
medium exchange. Formulation, fill and finish, and storage and distribution will complete processes prior to clinical 
administration. Source: Jossen et al. [67].
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(from Lonza, Australia), expanded as monolayer cultures, retain multilineage differentiation 
capacity, including neural marker expression, after 43 days of in vitro expansion in the com-
mercial synthetically defined human mesenchymal stem cell-growth media MSCGM-CD™ 
(Lonza, Australia) [96]. Therefore, these cells could in principle be a source for cell-based 
therapies of the nervous system.
The regenerative capacity of MSCs has been attributed to their anti-inflammatory immuno-
regulatory properties. Depending on the milieu composition, MSCs, in fact, exhibit anti- or 
pro-inflammatory properties (see Figure 4) [42, 97–100].
In an early stage of trauma or microbial invasion, when concentration of pro-inflammatory 
cytokines is low, MSCs present with antimicrobial pro-inflammatory properties of neutrophils 
[97–102]. As inflammation proceeds and pro-inflammatory cytokines build up, MSCs switch to 
an anti-inflammatory phenotype. Some of these anti-inflammatory actions include inhibition 
of anti-inflammatory activities of T cells, natural killer cells, and B cells; skewing macrophages 
to an M2 immunosuppressive state and monocyte-derived dendritic cells to a regulatory phe-
notype; and increasing their phagocytic capacity and inhibit mast cell degranulation [103, 104]. 
Increased immunomodulatory capacity of MSCs correlates with high levels of activated com-
plement C3 [105, 106]. As MSCs express the complement factor H and the complement regula-
tory protein CD59, MSCs are protected from lysis. All this endows MSCs with the potential to 
suppress uncontrolled immune responses making them a suitable candidate for inflammation 
and immune dysfunction therapeutics by themselves or in combination with other cell types.
4.2. Induced pluripotent stem cells (iPSCs)
NSPCs may differentiate into neural cells after transplantation into an injured spinal cord, 
replacing lost or damaged cells, providing trophic support, restoring connectivity, and facili-
tating regeneration as a large number of studies have reported [107]. NSPC has produced 
some degree of functional recovery. The fetal, adult brain and adult spinal cord are the main 
sources for NSPCs resulting in advantageous cells for transplantation because they can be 
expanded and self-renewed in culture. Fetal NSPCs can be expanded for long periods by 
in vitro conditions, while adult NSPCs have more limited capabilities.
Despite a large number of studies using NSPCs, reviewed by Mothe et al. [108], some impor-
tant issues such as isolation from their natural niche and their purification and expansion have 
to be taken in consideration [109]. Also, NSPCs have been reported to promote neuropathic 
pain, a concerning adverse effect. Most experimental SCI studies with NSPC transplants have 
involved rodent NSPCs because human NSPCs were either not available or difficult to grow. 
Human NSPCs have been isolated from the fetal brain and spinal cord of aborted fetuses [110] 
and postmortem tissue, but actually NSPCs can also be derived from human iPSCs [111].
Human iPSC-derived NSPCs have been transplanted into SCI models [112–114]. In these stud-
ies, nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice were used for 
SCI. The studies revealed an improved functional recovery with expression of neurotrophic 
factors from the grafted cells, axonal growth and stimulation of angiogenesis, increased 
myelination, and new forming synaptic connections between grafted cells and host neurons. 
In addition these studies showed the safety of human iPSC-derived NSPCs. All studies were 
performed in the subacute stage with just epicenter transplants.
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All the previous reports support the potential use of iPSC-derived NSPCs in SCI. They have 
significant advantages, such as the lack of ethical controversy regarding their source and the 
potential for providing autologous transplants, thus avoiding the risk of rejection or side effects 
associated with immunosuppression. Recent data demonstrated the effect of the microenviron-
ment of the injured spinal cord in the grafted iPSC-derived NSPCs. This pro-inflammatory 
environment induced proliferation of grafted cells [115]. Therefore, new approaches are 
needed to promote and guide cell differentiation, as well as to reduce tumorigenicity. Protocols 
for NSPC reprogrammed cells are actually improved to avoid rejection [116].
The most current iPSC protocols for neural differentiation require GFs or embryoid body 
formation, decreasing yields and limiting medical applications. Our lab recently developed 
a simple animal-free medium formula based on the inclusion of insulin and human extracel-
lular matrix components leading to direct conversion of >98% of iPSCs into expandable and 
functional neural progenitors with neural rosette characteristics [111]. Further differentiation 
into dopaminergic and spinal motoneurons as well as oligodendrocytes and astrocytes sup-
ports the proposal that these neural progenitors retain responsiveness to environmental cues 
supporting applicability of the protocol for the treatment of neurodegenerative diseases. The 
fact that this protocol avoids embryoid body formation makes it suitable for the clinic [111].
Formerly, a feeder-free, single-step, and quick (less than 40 days) generation of mature 
neurons from iPSC strategy using the chemically defined medium mTeSR from STEMCELL 
Figure 4. Immunomodulatory action of activated MSCs. Notes: Red arrow, stimulation; black arrow, suppression; blunt-
ended arrow, direct inhibition. Abbreviations: iDC, immature dendritic cell; IL, interleukin; HGF, hepatocyte growth 
factor; TGF-β, transforming growth factor-β; PGE-2, prostaglandin E2; IDO, indoleamine 2,3-dioxygenase; NO, nitric 
oxide; PD-L1, programmed death-ligand 1; hMSC, human mesenchymal stem cell; Treg, T regulatory; Th, T helper; 
CTL, cytotoxic T cell; mDC, mature dendritic cell; PD-1, programmed cell death protein 1; PMN, polymorphonuclear 
leukocyte; NK, NK cell. Source: Zachar et al. [97].
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Technologies, overcoming the need for embryoid body formation and neuronal rosette isola-
tion, was developed by Badja et al. Authors show that after induction the cells express volt-
age-gated and ionotrophic receptors for GABA, glycine, and acetylcholine (ACh) receptors 
and recommend the method to model human pathologies [117].
Apart from efficient differentiation methods, iPSC generation presents with the limitations 
of low reprogramming efficiencies (below 0.02%) and genetic modification requirements, 
as described by Yamanaka et al. [5, 6] and concurrently James Thompson’s group [7]; thus, 
chromosomal instability and tumorigenic potential derived from oncogene overexpression 
concerns arise for their use in the clinic. An advance for safety is provided by the use of poly-
cistronic plasmids to lead ectopic expression of the transcription factors OCT4, SOX2, KLF4, 
and C-MYC [118]. Other improvements based on the choice of somatic cell source, choice of 
reprogramming factors, culture procedures, and delivery methods have been described. For 
example, reprogramming kinetics and efficiencies vary between somatic cell types, in par-
ticular, keratinocytes reprogramed 2 times faster and 100 times more efficient than skin fibro-
blasts [10], and in general, immature cells are more readily reprogrammed than terminally 
differentiated cells [119]. The requirement of reprogramming factors also varies according to 
the cell type, so neural stem cells need only the introduction of OCT4 to be reprogrammed 
[120]. Reprogramming efficiency can be increased by different methods including adjustment 
of expression levels of noncoding RNAs, such as microRNAs or lincRNAs [111, 121]. ncRNAs 
can reduce the amount of reprogramming factors as they specifically target multiple path-
ways. Traditionally, lentivirus has been the reprogramming vector of choice; other viral vec-
tors such as Sendai and adenovirus to lower transformation risks have been used with lower 
efficacy [122–124]. Excellent reviews describing more details for reprogramming protocol 
improvements are available [125–127].
In addition to iPSC-derived NPCs, other neural types such as neurons or astrocytes have 
shown some potential for SCI recovery either to improve synaptic connections or reduce 
neuropathic pain for the first or to protect the lesion epicenter from infiltrating peripheral 
inflammatory cells for the second [122, 128]. Peripheral inflammatory cell infiltration can be 
reduced by the immunoregulatory functions of central nervous system perivascular stromal 
cells (PSCs). Their low abundance, inaccessibility, and limited proliferation capacity hampers 
its clinical use. However, PSCs can be successfully generated from iPSCs [129] and expanded 
in vitro without senescing. Thus, SCI stem cell-based therapeutics may benefit including PSCs 
as part of combinatorial treatments.
4.3. Preconditioning of stem cells
It may result advantageously to precondition MSCs or iPSCs before transplantation accord-
ing to the particular application or therapy, so that the cells are committed to a particular 
desired phenotype. Okolicsanyi et al. have more recently shown that heparan sulfate pro-
teoglycans (HSPGs) act as drivers of neural progenitors in expanded bone marrow-derived 
MSCs [96]. Treatment of MSCs with heparin increased proliferation in addition to the expres-
sion of neural markers although these changes were not uniform across growth phases indi-
cating that the direct lineage specifications and functionality of expanded cells might need 
fine-tuning. Nevertheless, the data sustains that MSCs may provide an abundant source that 
can be manipulated for purposes of neural repair and regeneration. Biomimetic approaches 
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to exploit the role of HSPGs in neurogenesis, such as synthetic glycopolymers or heparin 
conjugates, are being developed so that neural differentiation into specific lineages can be 
controlled and tailored [96, 130].
Stem cell transplantation has shown an important limitation due to its poor survival and 
engraftment at the injured spinal cord, where cells are exposed to hypoxic conditions, nutri-
tional deficiency, or oxidative stress among others. We recently showed that FM19G11, a 
small chemical, first described as a HIFα protein inhibitor, is able to allow progenitor cells 
to differentiate into more mature oligodendrocytes under hypoxia without cytotoxic effects 
at nanomolar doses [IC50 (80 nM)]. Moreover, FM19G11 induces self-renewal by inducing 
insulin-like signaling pathway and inducing ATP accumulation, activated glucose metabo-
lism with glucose uptake by upregulation of the GLUT4 transporter. The over-induction of 
AKT/mTOR signaling was directly correlated to the FM19G11-dependent induction of the 
self-renewal-related markers Sox2, Oct4, Nanog, and Notch1 [130]. Interestingly, the use of a 
combination of FM19G11 treatment and epSPC transplantation for SCI therapy reduced the 
glial scar extension and increased the number of neuronal fibers at the epicenter of the lesion. 
It also increased expression markers for neuronal plasticity and induced oligodendrocyte 
turnover for potential remyelination [131, 132].
In addition to preconditioning toward enhancing cell survival and proliferation or inducing 
differentiation into particular cell types, various treatments have shown to impact MSC sec-
retome which could be advantageous for particular therapies. For example, the treatment of 
MSCs with IL-1β increases the expression levels of a number of cytokines and chemokines as 
well as induces the expression of cell adhesion molecules improving the migration ability of 
preconditioned cells to the site of inflammation in vivo [133]. Preconditioning protocols typi-
cally include physical treatments such as different degrees of hypoxia, mechanical stretching, 
application of electromagnetic fields or mimicking of three-dimensional environments on 
one side, and chemical or pharmacological treatments, including herbal medicines or natural 
extracts on another. For a recent quite complete review of preconditioning treatments of MSCs 
and their effects, readers are directed to the review by Hu and Li [134]. It is interesting to note 
that preconditioning of MSCs with low-dose lipopolysaccharide (LPS), a major component of 
Gram-negative bacteria, preserves mitochondrial membrane potential inhibiting cytochrome 
c release in hypoxia serum-deprived cultured cells [135], suggesting that a mild local infection 
could in fact potentiate stem cell treatment. Therefore, it should be taken into account that 
patients undergoing stem cell therapies are often subjected to additional pharmacological 
treatments and exposed to particular environmental factors which may impact the perfor-
mance of the introduced stem cells at the post-implant level. To circumvent the uncertainty 
associated with these hard-to-control variables, genetic modification of MSCs toward the pro-
duction of defined immunoregulatory effects or homing molecules is starting to be explored. 
For example, EAE was shown to be consistently attenuated by using engineered MSCs with 
CNS-homing ligand genes along with overexpression of IL-10 [136].
4.4. Extracellular vesicle-based therapeutics
Although autologous MSCs constitute a safer choice in terms of avoiding unwanted immune 
responses, donor comorbidities may hamper the use of their own stem cells. Expanded allo-
geneic MSCs were initially believed to be immune privileged due to their low expression of 
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major histocompatibility complex (MHC) and costimulatory molecules and the fact that they 
can suppress the activity of numerous immune cell populations [42–45]. Despite the overall 
safety reported by a large number of CTs [25, 41, 45], substantial evidence now supports both 
cell-mediated and humoral immune responses against donor antigens following adminis-
tration of these cells highlighting that MSCs can be recognized by the host immune system 
(reviewed by Berglund et al. and Lohan et al.) [137, 138]. On another end, iPSCs are envisioned 
as a source to eliminate immune rejection; however, this remains theoretical, as therapeutic 
human trials have yet to be conducted. It will be important to monitor DNA methylation 
status and gene expression changes that could evoke immune responses in transplanted hosts 
even if iPSCs are autologously derived. Therefore, the possibility of a therapeutic cell-free 
product could be highly relevant on safety terms.
GFs and cytokines packed and secreted by MSCs (secretome) are thought to play a significant 
role in SCI repair, mainly by lowering pro-inflammatory cytokines (i.e., IL-2 or IL-6 and TNF-
α) [139]. In fact, Cizkova et al. attributed motor function recovery, attenuated inflammatory 
response, and spared spinal cord tissue to a molecular cocktail found in the MSCs after trans-
plantation [140]. MSC paracrine secretion or secretome was first described by Haynesworth 
et al. in 1996 [141]; since then multiple actions are endowed to MSC secretome rather than 
to their engraftment. Such actions include increased angiogenesis, decreased apoptosis and 
fibrosis, enhanced neuronal survival and differentiation, restriction of local inflammation, 
and adjustment of immune responses, effects that translate into induction of regeneration 
of damaged tissues [142]. Therefore, the therapeutic value of stem cells may mainly derive 
from the released factors or secretome including soluble and vesicle-packed factors. This lat-
ter fraction, termed extracellular vesicles (EVs), is a heterogeneous mix of vesicles including 
exosomes, a subset of double-membrane vesicles characterized by the expression of a set of 
markers, including tetraspanins CD9, CD63, and CD81 with attributed intercellular commu-
nication role including the transfer of their cargo (DNA, RNA, and proteins) [143].
The first documented clinical administration of EVs was performed in 2011, by administration 
of EVs intravenously infused at intervals of 2 or 3 days during a period of 2 weeks to a steroid-
refractory GvHD patient who showed declined symptoms and stability for over 4 months 
[144]. Many preclinical models have shown the benefit of EV-based therapy including long-
term neuroprotection. Treatment with MSC-derived EVs promoted long-lasting recovery of 
cognitive functions in inflammation-induced preterm brain injury [145]. EV-based therapy 
of SCI in rats showed a reduction of inflammatory response with apparent astrocyte and 
microglia disorganization in cord tissue up to 10 mm caudal to the injury site as well as loco-
motor recovery [146]. This illustrates the multiple potential benefits of EV-based therapies 
to treat neuroimmune defects. EV superiority with respect to cell-based therapeutics resides 
in its ready availability, ease of storage and distribution, reduced immunoantigenicity, scal-
ability, and possibility of multiple routes of administration. EVs can also be used as delivery 
particles by directionally packaging molecules of interest from genetically modified cells 
while avoiding the risk of transfer of transformed live cells and could be obtained from iPSCs 
as well. Guidelines and recommendations for production, quality assurance, and application 
of EV-based therapeutics have been provided in an International Society for Extracellular 
Vesicles (ISEV) and European Network on Microvesicles and Exosomes in Health and 
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Disease (ME-HaD) position paper [147]. Also, the International Council for Harmonization 
of Technical Requirements for Pharmaceuticals of Human Use (ICH) mission guidelines to 
ensure the production of safe and effective high-quality medicines can be accessed on the 
following link: http://www.ich.org/products/guidelines.
Although clinical trials using EVs are still seldom, several companies have already engaged 
in EV or secretome production. A list of these companies with the corresponding links to their 
web pages can be found in the recent review by Gimona et al. [148]. This review includes a 
further in-depth review of clinical-grade EV production current status and remaining chal-
lenges. Involvement of biobank networks with pharmaceuticals may be relevant for granting 
standardized GMP production consistency of EVs [149].
Lastly, it should be mentioned that EVs can also be used as a sensor of stem cell plasticity or 
other cell features as they reflect characteristics of the cell of origin [150] constituting a helpful 
tool to develop optimized differentiation and preconditioning protocols.
5. Conclusions
Although CTs have in general evidenced MSC safety, the removal of FBS from clinical-grade 
stem cell protocols results imperative. The pooling of a large number of donors of cells and 
human blood fraction-based media through the use of stem cell banks or the use of xeno-free 
synthetic defined media should translate into allogeneic MSC preparations leading to more 
homogeneous clinical results. Thus, allowing minimal immune-related safety concerns derived 
from FBS and unveiling the real therapeutic value of in vitro expanded off-the-shelf MSCs.
The iPSC manufacturing technology offers the possibility of developing patient-tailored cell 
therapies with the consequent safety and immune-related advantages, as genetically identical 
cells should prevent immune rejection. iPSCs can differentiate into all three germ layers and, 
by their nature, do not raise bioethical debate. However, safety concerns related to in vivo 
properties of immortal cell types and the use of genetically manipulated cells raise regulation 
hurdles for their use in the clinic.
Preconditioning of in vitro expanded MSCs to ensure cell lineage commitment might result 
advantageously for improved treatment of particular diseases. Optimizations for the treat-
ment of SCI and other neuroimmune health problems such as ME/CFS remain. Also, EVs and 
in particular exosome-enriched MSC-derived fractions may eventually become the treatment 
of choice for cell-based-free therapeutics by themselves or in combination with other clinical 
treatments once GMP production is optimized.
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